scholarly journals Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys

2017 ◽  
Vol 25 (10) ◽  
pp. 2323-2331 ◽  
Author(s):  
Diogo M. Magnani ◽  
Michael J. Ricciardi ◽  
Varian K. Bailey ◽  
Martin J. Gutman ◽  
Núria Pedreño-Lopez ◽  
...  
2005 ◽  
Vol 49 (11) ◽  
pp. 4508-4514 ◽  
Author(s):  
C. Ajariyakhajorn ◽  
M. P. Mammen ◽  
T. P. Endy ◽  
M. Gettayacamin ◽  
A. Nisalak ◽  
...  

ABSTRACT Dengue fever and dengue hemorrhagic fever are caused by infection with any one of the four dengue viruses (DVs) and are significant public health burdens throughout the tropics. Higher viremia levels are associated with greater dengue disease severity. A therapeutic intervention to suppress viremia early in DV infection could potentially ameliorate severe disease. Recombinant alpha interferon 2a (rIFN-α-2a, Roferon-A) suppressed DV replication in human peripheral blood mononuclear cells in vitro. We therefore examined the effects of rIFN-α-2a and pegylated recombinant IFN-α-2a (PEG-rIFN-α-2a, PEGASYS) on DV serotype 2 (DV-2) viremia in rhesus monkeys. Flavivirus-naïve monkeys were inoculated with DV-2 and randomized to receive a single dose of rIFN-α-2a (10 million international units/m2) versus placebo or PEG-rIFN-α-2a (6 μg/kg) versus placebo 1 day after the onset of viremia. Serial daily viremia levels were measured, and convalescent-phase DV-2 neutralizing antibody titers were determined. Compared to placebo, a single injection of rIFN-α-2a temporarily suppressed DV-2 replication and delayed the time to peak viremia by a median of 3 days. However, measures of total viral burden were not different between the two groups. A single injection of PEG-rIFN-α-2a significantly lowered daily viremia levels and improved virus clearance, starting 48 h after administration. There were no significant differences in DV-2 neutralizing antibody titers between the treatment and placebo groups at 30 and 90 days postinfection. Based on their individual effects, future studies should investigate a combination of rIFN-α-2a and PEG-rIFN-α-2a for suppression of dengue virus viremia and as a potential therapeutic intervention.


Virus Genes ◽  
2017 ◽  
Vol 54 (1) ◽  
pp. 25-32 ◽  
Author(s):  
J. Asnet Mary ◽  
Akanitt Jittmittraphap ◽  
Siriporn Chattanadee ◽  
Pornsawan Leaungwutiwong ◽  
R. Shenbagarathai

2007 ◽  
Vol 102 (2) ◽  
pp. 203-208 ◽  
Author(s):  
MS Freire ◽  
RS Marchevsky ◽  
LFC Almeida ◽  
AMY Yamamura ◽  
EC Caride ◽  
...  
Keyword(s):  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Daniela V. Andrade ◽  
Colin Warnes ◽  
Ellen Young ◽  
Leah C. Katzelnick ◽  
Angel Balmaseda ◽  
...  

Abstract The four dengue virus serotypes (DENV1-4) cause major public health problems worldwide. Highly neutralizing type-specific human monoclonal antibodies (hmAbs) target conformation-dependent epitopes on the DENV envelope protein, including 1F4, a DENV1 type-specific hmAb. Using a recombinant DENV2 virus displaying the DENV1 1F4 epitope (rDENV2/1), we measured the proportion and kinetics of DENV1 neutralizing antibodies targeting the 1F4 epitope in individuals living in Asia and the Americas where different DENV1 genotypes were circulating. Samples from 20 individuals were analyzed 3 and 18 months post-primary DENV1 infection, alongside samples from 4 individuals collected annually for four years post-primary DENV1 infection, from two studies in Nicaragua. We also analyzed convalescent post-primary DENV1 plasma samples from Sri Lankan individuals. We found that neutralizing antibodies recognizing the 1F4 epitope vary in prevalence across both populations and were detected from 20 days to four years post-infection. Additionally, both populations displayed substantial variability, with a range of high to low proportions of DENV1 type-specific neutralizing antibodies recognizing the 1F4 epitope seen across individuals. Thus, the 1F4 epitope is a major but not exclusive target of type-specific neutralizing antibodies post-primary infection with different DENV1 genotypes in Asia and Latin America, and additional epitopes likely contribute to type-specific neutralization of DENV1.


2015 ◽  
Vol 89 (12) ◽  
pp. 6494-6505 ◽  
Author(s):  
Raphaël M. Zellweger ◽  
William W. Tang ◽  
William E. Eddy ◽  
Kevin King ◽  
Marisa C. Sanchez ◽  
...  

ABSTRACTDengue virus (DENV) is a major public health threat worldwide. Infection with one of the four serotypes of DENV results in a transient period of protection against reinfection with all serotypes (cross-protection), followed by lifelong immunity to the infecting serotype. While a protective role for neutralizing antibody responses is well established, the contribution of T cells to reinfection is less clear, especially during heterotypic reinfection. This study investigates the role of T cells during homotypic and heterotypic DENV reinfection. Mice were sequentially infected with homotypic or heterotypic DENV serotypes, and T cell subsets were depleted before the second infection to assess the role of DENV-primed T cells during reinfection. Mice primed nonlethally with DENV were protected against reinfection with either a homotypic or heterotypic serotype 2 weeks later. Homotypic priming induced a robust neutralizing antibody response, whereas heterotypic priming elicited binding, but nonneutralizing antibodies. CD8+T cells were required for protection against heterotypic, but not homotypic, reinfection. These results suggest that T cells can contribute crucially to protection against heterotypic reinfection in situations where humoral responses alone may not be protective. Our findings have important implications for vaccine design, as they suggest that inducing both humoral and cellular responses during vaccination may maximize protective efficacy across all DENV serotypes.IMPORTANCEDengue virus is present in more than 120 countries in tropical and subtropical regions. Infection with dengue virus can be asymptomatic, but it can also progress into the potentially lethal severe dengue disease. There are four closely related dengue virus serotypes. Infection with one serotype results in a transient period of resistance against all serotypes (cross-protection), followed by lifelong resistance to the infecting serotype, but not the other ones. The duration and mechanisms of the transient cross-protection period remain elusive. This study investigates the contribution of cellular immunity to cross-protection using mouse models of DENV infection. Our results demonstrate that cellular immunity is crucial to mediate cross-protection against reinfection with a different serotype, but not for protection against reinfection with the same serotype. A better understanding of the mediators responsible for the cross-protection period is important for vaccine design, as an ideal vaccine against dengue virus should efficiently protect against all serotypes.


2014 ◽  
Vol 8 (10) ◽  
pp. e3230 ◽  
Author(s):  
Darunee Buddhari ◽  
Jared Aldstadt ◽  
Timothy P. Endy ◽  
Anon Srikiatkhachorn ◽  
Butsaya Thaisomboonsuk ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document